Table 3. Association of the BRAF V600E mutation with clinicopathological features of the PTC cases found by mass screening.
| BRAFV600E | Rearrangement or unknown mutation | Univariate p-value; OR (95% CI) | Multivariate p-value; OR or B (95% CI) | |
|---|---|---|---|---|
| All PTC cases | 43 | 20 | ||
| Age at operation (y.o. ± s.d.) | 18.2 ± 2.3 | 16.7 ± 3.7 | 0.115a | 0.041; B = 1.629 (0.068–3.190)c |
| Sex | 0.155b; OR = 2.880 (0.823–10.076) | 0.089; OR = 3.115 (0.841–11.494)e | ||
| M | 18 | 4 | ||
| F | 25 | 16 | ||
| Tumor size (mm ± s.d.) | 12.2 ± 6.8 | 18.3 ± 9.5 | 0.002a | 0.005; B = -6.547 (−11.060–−2.034)d |
| Microcarcinoma | 0.012b; OR = 5.937(1.515–23.260) | 0.037; OR = 4.477 (1.095–18.303)f | ||
| ≤10 mm | 22 | 3 | ||
| >10 mm | 21 | 17 | ||
| Histology | 0.097b; OR = 11.757(0.537–257.210) | Not performed because of no FV in the BRAFV600E group | ||
| CP | 43 | 18 | ||
| FV | 0 | 2 | ||
| pT | 0.103b; OR = 2.840(0.942–8.566) | 0.086; OR = 2.779 (0.866–8.923)f | ||
| pT1 or 2 | 26 | 7 | ||
| pT3 | 17 | 13 | ||
| pN | 0.714b; OR = 0.667(0.165–2.692) | 0.783; OR = 0.800 (0.164–3.917)f | ||
| pN0 | 6 | 4 | ||
| pN1a or 1b | 36 | 16 | ||
| M | 0.090b; OR = 0.080(0.004–1.764) | Not performed because of no M in the BRAFV600E group | ||
| M0 | 43 | 17 | ||
| M1 | 0 | 2 | ||
| pEx | 0.109b; OR = 0.388(0.129–1.166) | 0.096; OR = 0.370 (0.115–1.193)f | ||
| pEx0 | 18 | 13 | ||
| pEx1 | 25 | 7 |
aMann-Whitney test.
bFisher’s exact test.
cLinear regression adjusted for sex.
dLinear regression adjusted for age and sex.
eLogistic regression adjusted for age.
fLogistic regression adjusted for age and sex. OR: odds ratio, B: regression coefficient, CI: confidential interval, CP: classic papillary, FV: follicular variant.